Mast Therapeutics Inc (MSTX) Lowered to “Neutral” at Laidlaw
Mast Therapeutics Inc (NASDAQ:MSTX) was downgraded by Laidlaw to a “neutral” rating in a research report issued on Wednesday.
Several other equities analysts have also recently commented on MSTX. Roth Capital reissued a “buy” rating and set a $8.00 target price on shares of Mast Therapeutics in a research report on Thursday, June 9th. Maxim Group reissued a “buy” rating and set a $5.00 target price on shares of Mast Therapeutics in a research report on Thursday, June 9th. Zacks Investment Research cut shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. Finally, Canaccord Genuity reissued a “buy” rating and set a $3.00 target price on shares of Mast Therapeutics in a research report on Thursday, July 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $3.33.
Shares of Mast Therapeutics (NASDAQ:MSTX) traded down 81.1017% during midday trading on Wednesday, hitting $0.1115. The company had a trading volume of 106,253,124 shares. Mast Therapeutics has a 12-month low of $0.10 and a 12-month high of $0.71. The company’s 50-day moving average price is $0.46 and its 200 day moving average price is $0.38. The company’s market capitalization is $23.62 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/mast-therapeutics-inc-mstx-lowered-to-neutral-at-laidlaw.html
Mast Therapeutics (NASDAQ:MSTX) last posted its earnings results on Tuesday, August 9th. The company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Equities research analysts predict that Mast Therapeutics will post ($0.21) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Mast Therapeutics stock. Vanguard Group Inc. increased its stake in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned 3.11% of Mast Therapeutics worth $2,818,000 as of its most recent filing with the SEC.
About Mast Therapeutics
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.